PMID- 30658624
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20200225
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Jan 18
TI  - Efficacy of (99m)Tc-DTPA SPECT/CT in diagnosing Orbitopathy in graves' disease.
PG  - 10
LID - 10.1186/s12902-019-0340-0 [doi]
LID - 10
AB  - BACKGROUND: The most frequently used methods of assessing Graves' orbithopathy 
      (GO) include: Clinical Activity Score (CAS), ultrasonography (USG), computed 
      tomography (CT), and magnetic resonance imaging (MRI). There exists another, 
      slightly forgotten, imaging method: single-photon emission computed tomography 
      (SPECT) with the use of diethylenetriaminepentaacetic acid tagged with (99m)Tc 
      ((99m)Tc-DTPA). These days it is possible to conduct a SPECT examination fused 
      with a CT scan (SPECT/CT), which increases the diagnostic value of the 
      investigation. The aim of this paper is to evaluate the usefulness of 
      (99m)Tc-DTPA SPECT/CT in diagnosing Graves orbitopathy, as compared with other 
      methods. METHODS: Twenty-three patients with suspected active 
      (infiltrative-edematous) Graves' orbithopathy were included in the study. Each 
      patient underwent a CAS, an MRI, and a SPECT/CT. The obtained results were 
      analysed statistically, with the assumed statistical significance of p < 0.05. 
      RESULTS: The SPECT/CT and MRI were found to have the highest sensitivity: 0.93 
      each. The SPECT/CT had the highest specificity: 0.89. MRI and CAS had lower 
      values: 0.78 and 0.56, respectively. The occurrence of an active form of GO had 
      no impact on the exacerbation of exophthalmos or the thickness of the oculomotor 
      muscles. CONCLUSIONS: The (99m)Tc-DTPA SPECT/CT method provides a very good tool 
      for assessing the active form of GO and can, alongside the MRI scan, be used as a 
      referential diagnostic procedure in GO.
FAU - Szumowski, Piotr
AU  - Szumowski P
AUID- ORCID: 0000-0001-8178-6583
AD  - Department of Nuclear Medicine, Medical University of Bialystok, M. 
      Sklodowskiej-Curie St. 24A, 15-276, Bialystok, Poland. piotrmjs@wp.pl.
FAU - Abdelrazek, Saeid
AU  - Abdelrazek S
AD  - Department of Nuclear Medicine, Medical University of Bialystok, M. 
      Sklodowskiej-Curie St. 24A, 15-276, Bialystok, Poland.
FAU - Zukowski, Lukasz
AU  - Zukowski L
AD  - Department of Nuclear Medicine, Medical University of Bialystok, M. 
      Sklodowskiej-Curie St. 24A, 15-276, Bialystok, Poland.
FAU - Mojsak, Malgorzata
AU  - Mojsak M
AD  - Department of Nuclear Medicine, Medical University of Bialystok, M. 
      Sklodowskiej-Curie St. 24A, 15-276, Bialystok, Poland.
FAU - Sykala, Monika
AU  - Sykala M
AD  - Department of Nuclear Medicine, Medical University of Bialystok, M. 
      Sklodowskiej-Curie St. 24A, 15-276, Bialystok, Poland.
FAU - Siewko, Katarzyna
AU  - Siewko K
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, M. Sklodowskiej-Curie St. 24A, 15-276, Bialystok, 
      Poland.
FAU - Maliszewska, Katarzyna
AU  - Maliszewska K
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, M. Sklodowskiej-Curie St. 24A, 15-276, Bialystok, 
      Poland.
FAU - Poplawska-Kita, Anna
AU  - Poplawska-Kita A
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, M. Sklodowskiej-Curie St. 24A, 15-276, Bialystok, 
      Poland.
FAU - Mysliwiec, Janusz
AU  - Mysliwiec J
AD  - Department of Nuclear Medicine, Medical University of Bialystok, M. 
      Sklodowskiej-Curie St. 24A, 15-276, Bialystok, Poland.
LA  - eng
PT  - Journal Article
DEP - 20190118
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Radiopharmaceuticals)
RN  - VW78417PU1 (Technetium Tc 99m Pentetate)
SB  - IM
MH  - Adult
MH  - Female
MH  - Graves Ophthalmopathy/*diagnostic imaging/physiopathology
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Middle Aged
MH  - Radiopharmaceuticals/*therapeutic use
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Technetium Tc 99m Pentetate/*therapeutic use
MH  - *Tomography, Emission-Computed, Single-Photon
PMC - PMC6339418
OTO - NOTNLM
OT  - 99mTc-DTPA
OT  - Graves' orbitopathy
OT  - MRI
OT  - SPECT/CT
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All procedures performed in studies 
      involving human participants were in accordance with the ethical standards of the 
      institutional and/or national research committee and with the 1964. Helsinki 
      declaration and its later amendments or comparable ethical standards. The study 
      was approved by the bioethical commission of Medical University of Bialystok, 
      Poland. All participants provided written informed consent to participate. 
      COMPETING INTERESTS: The authors declare that they have no competing interests. 
      PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2019/01/20 06:00
MHDA- 2019/05/24 06:00
PMCR- 2019/01/18
CRDT- 2019/01/20 06:00
PHST- 2018/09/30 00:00 [received]
PHST- 2019/01/10 00:00 [accepted]
PHST- 2019/01/20 06:00 [entrez]
PHST- 2019/01/20 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2019/01/18 00:00 [pmc-release]
AID - 10.1186/s12902-019-0340-0 [pii]
AID - 340 [pii]
AID - 10.1186/s12902-019-0340-0 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2019 Jan 18;19(1):10. doi: 10.1186/s12902-019-0340-0.